|
|
|
| Bibliometric and visualization analysis of research on pathogenesis of myelodysplastic syndromes |
| XU Hao TAO Yuchen HU Kexin XUE Tingting WANG Yanlu LIANG Chenhui DONG Xiaojie LU Jiahui |
| Department of Hematology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200071, China |
|
|
|
Abstract Objective To explore the current status and development trend of the pathogenesis of myelodysplastic syndromes (MDS). Methods Using Web of Science core collection as data source, combined with the visualization function of CiteSpace software, the literature information (journals, authors, institutions, countries, keywords, and highly cited literatures) on the pathogenesis of MDS from January 2011 to December 2020 were analyzed. Results A total of 941 articles were included. The journal with the most publications was Blood, and the author with the most publications was Jaroslaw P. Maciejewski from the cleveland clinic in the United States. The university of Texas MD Anderson Cancer Center was the institution with the most published literature. A total of 13 keyword clusters and 14 emergent keywords were found. Keywords with higher frequency include acute myeloid leukemia, hematopoietic stem cells, somatic mutations, and gene expression, etc. Conclusion The research field of MDS pathogenesis has made great progress. The main research directions include clonal hematopoiesis, somatic gene mutation, bone marrow microenvironment, and immune abnormalities. The development of various new drugs for pathogenesis will become the future research trend.
|
|
|
|
|
|
[1] Montalban-Bravo G，Garcia-Manero G. Myelodysplastic syndromes：2018 update on diagnosis，risk-stratification and management [J]. Am J Hematol，2018，93（1）：129-147.
[2] Elias HK，Schinke C，Bhattacharyya S，et al. Stem cell origin of myelodysplastic syndromes [J]. Oncogene，2014， 33（44）：5139-5150.
[3] Cazzola M. Myelodysplastic Syndromes [J]. N Engl J Med，2020，383（14）：1358-1374.
[4] Bennett JM，Catovsky D，Daniel MT，et al. Proposals for the classification of the myelodysplastic syndromes [J]. Br J Haematol，1982，51（2）：189-199.
[5] 刘家希，王化泉.骨髓增生异常综合征诊断和治疗进展[J].中国癌症防治杂志，2017，9（2）：158-163.
[6] 高俊宽.文献计量学方法在科学评价中的应用探讨[J].图书情报知识，2005（2）：14-17.
[7] Chen C. CiteSpace Ⅱ：Detecting and visualizing emerging trends and transient patterns in scientific literature [J]. J Am Soc Inf Sci Tech，2006，57（3）：359-377.
[8] Liu Z，Yin Y，Liu W，et al. Visualizing the intellectual structure and evolution of innovation systems research： a bibliometric analysis [J]. Scientometrics，2015，103（1）：135-158.
[9] Synnestvedt MB，Chen C，Holmes JH. CiteSpace Ⅱ：visualization and knowledge discovery in bibliographic databases [J]. AMIA Annu Symp Proc，2005：724-728.
[10] 施均.我如何理解克隆性造血的临床问题[J].中华血液学杂志，2018，39（11）：895-897.
[11] Papaemmanuil E，Gerstung M，Malcovati L，et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes [J]. Blood，2013，122（22）：3616-3627；quiz 3699.
[12] Yoshida K，Sanada M，Shiraishi Y，et al. Frequent pathway mutations of splicing machinery in myelodysplasia [J]. Nature，2011，478（7367）：64-69.
[13] 肖志坚.骨髓增生异常综合征诊断的方法学：现况与问题[J].国际输血及血液学杂志，2019，42（2）：93-97.
[14] Della Porta MG. Myelodysplastic syndromes and bone marrow microenvironment [J]. Leuk Res，2011，35（11）：1442-1443.
[15] Jiang XX，Zhang Y，Liu B，et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells [J]. Blood，2005，105（10）：4120-4126.
[16] Davies LC，Heldring N，Kadri N，et al. Mesenchymal Stromal Cell Secretion of Programmed Death-1 Ligands Regulates T Cell Mediated Immunosuppression [J]. Stem Cells，2017，35（3）：766-776.
[17] 欧阳，吴俣.骨髓增生异常综合征免疫异常机制的研究新进展[J].国际输血及血液学杂志，2021，44（1）：22-28.
[18] Glenth?覬j A，?覫rskov AD，Hansen JW，et al. Immune Mechanisms in Myelodysplastic Syndrome [J]. Int J Mol Sci，2016，17（6）：944.
[19] Sallman DA，DeZern AE，Garcia-Manero G，et al. Eprenetapopt （APR-246） and Azacitidine in TP53-Mutant Myelodysplastic Syndromes [J]. J Clin Oncol，2021，39（14）：1584-1594.
[20] Winters AC，Maloney KW，Treece AL，et al. Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia [J]. Pediatr Blood Cancer，2020，67（10）：e28398.
[21] Navada SC，Garcia-Manero G，OdchimarReissig R，et al. Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia：Results of a phase 1 study [J]. Leuk Res，2020， 94：106369.
[22] Caravella JA，Lin J，Diebold RB，et al. Structure-Based Design and Identification of FT-2102 （Olutasidenib），a Potent Mutant-Selective IDH1 Inhibitor [J]. J Med Chem，2020，63（4）：1612-1623.
[23] Sikic BI，Lakhani N，Patnaik A，et al. First-in-Human，First-in-Class Phase Ⅰ Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers [J]. J Clin Oncol，2019，37（12）：946-953.
[24] Curigliano G，Gelderblom H，Mach N，et al. Phase Ⅰ/Ⅰb Clinical Trial of Sabatolimab，an Anti-TIM-3 Antibody，Alone and in Combination with Spartalizumab，an Anti-PD-1 Antibody，in Advanced Solid Tumors [J]. Clin Cancer Res，2021，27（13）：3620-3629.
[25] Fenaux P，Platzbecker U，Mufti GJ，et al. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes [J]. N Engl J Med，2020，382（2）：140-151. |
|
|
|
